Shop on Impakter Eco
  • Women
  • Men
  • Kids
  • Beautycare
  • Home & Living
  • Food & Drinks
  • Pets
Impakter
  • Shop Eco
  • Culture
    • Art
    • Cinema
    • Entertainment
    • Literature
    • Music
    • Photography
  • Style
    • Architecture
    • Design
    • Fashion
    • Foodscape
    • Lifestyle
  • Society
    • Business
    • Environment
    • Foreign Affairs & Politics
    • Health
    • Tech
    • Science
    • Start-up
  • Impact
    • Eco Life
    • Circular Economy
    • COP26
    • CityLife
      • Copenhagen
      • San Francisco
      • Seattle
      • Sydney
    • Sustainability Series
      • SDGs Series
      • Shape Your Future
      • 2030: Dream or Reality
    • Philanthropy
      • United Nations
      • NGO & Charities
      • Essays
    • Your Voice
      • Empower Earth
      • Empower Equality
  • SUSTAINABILITY INDEX
  • Startup-Hub
    • Companies
    • Investors
    • Organisations
    • Jobs
    • Events
  • Partners
  • About
    • Team
    • Global Leaders
    • Contributors
    • Write for Impakter
    • IMPAKTER Italy
    • Republishing Content
    • Permissions and Copyright
    • Privacy Policy
    • Contact
No Result
View All Result
Impakter
No Result
View All Result
Home Society Health

FDA Approval to Boost Confidence in Covid Vaccines

Pfizer Goes from Emergency to Full Approval - What Comes next?

Isaac Castella-McDonaldbyIsaac Castella-McDonald
August 24, 2021
in Health, Society
Pfizer
Share on FacebookShare on Twitter

This week the Pfizer vaccine completed the U.S. Food and Drug Administration’s (FDA) approval process. This is an important step forward to convince the still large number of Americans who are vaccine-hesitant or straight out anti-vaxxers, a group that will be much harder to convince. 

A recent survey found that 22% of Americans identify themselves as anti-vax — with 8% “always” identifying with the term. 80 million Americans were unvaccinated in late July.

The vaccine is now officially approved for adults, after having been brought to the population under emergency use authorisation in December 2020. 

Under this emergency authorisation the FDA required only two months of safety monitoring data on study subjects. Along with the Moderna and Johnson & Johnson vaccines, these tests were carried out on tens of thousands of people, and covered the time period in which side effects are most likely to arise.

This allowed the vaccine to be brought to populations much sooner, saving lives and beginning the long process of recovery from the pandemic. As of today, more than 204 million doses have been administered in the U.S., and many more globally.

The FDA concluded their review of six months of follow-up data this week. Their review conducted clinical trials as well as monitoring the quality and safety of the manufacturing process. 

The full approval is the FDA’s strongest endorsement of the jabs safety and effectiveness.

On Monday, President Biden urged the population to take confidence in this decision: “If you’re one of the millions of Americans who said that they will not get the shot until it has full and final approval of FDA: It has now happened. The moment you’ve been waiting for is here.”

The FDA’s full approval has bolstered confidence from organisations to take the controversial step in mandating vaccination. New York City said it would require vaccination for all teachers before the school year. The Pentagon said it would mandate vaccination for 1.4 million troops on active duty by September.


Related Articles: Future Pandemics: Act Now or Pay More Later – How One Health and Prototype Vaccines Shift the Odds | Anti-Vaxxers and Vaccine Hesitancy: A Cottage Industry Gone Big Time | Global Health Summit: Can Europe End Vaccine Inequities?

While some have insisted that the approval is meaningless given the hundreds of millions of people who have been given the vaccine, John Moore, a virologist at Weill Cornell Medicine, sees this as an important milestone:

“I think a substantial number of people will be stepping up and taking the vaccine now that there’s full approval. Employers, a significant number of them, are going to have more legal and moral confidence in putting in vaccine mandates.”

Personal sovereignty clashes with collective well-being in the issue of COVID vaccine mandates and COVID passports. In a non-emergency situation, it would be illegal for governments or companies to mandate a medical product to their employees. 

The central question is whether or not the pandemic justifies the waiving of this freedom in the name of the greater good. 

Full FDA approval of the Pfizer vaccine is another step forward – to convince more people to get vaccinated, to facilitate mandates, and to save more lives.

Moderna's full approval shouldn't be far behind – just a matter of timing and paperwork.

— Dr. Tom Frieden (@DrTomFrieden) August 23, 2021

This approval only applies to its use for over-16s, and it leaves some basic questions still unanswered. For one thing, it does not apply to booster jabs. Moreover, a big slice of the population – the 12- to 15-year-olds – are still authorised to receive the jab under the emergency use authorisation granted to Pfizer in the early stages of this year. 

In short, the FDA’s approval process is not done yet. And if it is true that it will help in convincing anti-vaxxers to submit to vaccination, then there is still work ahead for the FDA to provide the assurance sought by people who are still vaccine-hesitant. 


Editor’s Note: The opinions expressed here by Impakter.com columnists are their own, not those of Impakter.com. — In the Featured Photo: Vials of the Pfizer vaccine. Featured Photo Credit: Marco Verch.

Previous Post

Totem GT, A True Electrified Icon

Next Post

International Shipping Responsible for 2% of Global CO2 Emissions

Isaac Castella-McDonald

Isaac Castella-McDonald

Isaac is an undergraduate reading English at Jesus College, Cambridge. His research interests include the subaltern, ecological criticism, and the invention of race. He grew up in Oxfordshire and was involved in local start-ups by the age of 16, working at Global Academy Jobs and dWell Housing. He’s held editing positions for The Cambridge Student and has been published in Varsity, Eliot’s Face, BAIT, and notes for his journalism and poetry. He enjoys travel and music, and has spent time living in Costa Rica and Kenya as well as the UK.

Related Posts

The 1977 White House Climate Memo That Should Have Changed the World
Environment

The 1977 White House Climate Memo That Should Have Changed the World

June 25, 2022
How Britain’s Bill of Rights Would Affect Human Rights, International Law, and the UK
Equal Rights

How Britain’s Bill of Rights Would Affect Human Rights, International Law, and the UK

June 24, 2022
EU Council Opens the Door to Ukraine and Moldova: What it Means
Politics & Foreign Affairs

EU Council Opens the Door to Ukraine and Moldova: What it Means

June 24, 2022
Next Post
International Shipping Responsible for 2% of Global CO2 Emissions

International Shipping Responsible for 2% of Global CO2 Emissions

Recent News

The 1977 White House Climate Memo That Should Have Changed the World

The 1977 White House Climate Memo That Should Have Changed the World

June 25, 2022
How Britain’s Bill of Rights Would Affect Human Rights, International Law, and the UK

How Britain’s Bill of Rights Would Affect Human Rights, International Law, and the UK

June 24, 2022
EU Council Opens the Door to Ukraine and Moldova: What it Means

EU Council Opens the Door to Ukraine and Moldova: What it Means

June 24, 2022
impakter-logo-light

Impakter informs you through the eco news site and empowers your sustainable lifestyle with its eco products marketplace.

Visit here IMPAKTER ECO for your eco products needs.

Registered Office Address

32 Lots Road, London
SW10 0QJ, United Kingdom


IMPAKTER Limited

Company number: 10806931

Impakter is a publication that is identified by the following International Standard Serial Number (ISSN) is the following 2515-9569 (Printed) and 2515-9577 (online – Website).


Office Hours - Monday to Friday

9.30am - 5.00pm CEST


Email

stories [at] impakter.com

About Us

  • Team
  • Contributors
  • Privacy Policy
  • Contact
  • Partners

By Audience

  • Lifestyle
  • Green Finance
  • Culture
  • Society
  • Style
  • Impact

Impakter Platforms

  • Media
  • Up
  • Index
  • Eco for Sellers
  • Impakter Pro

© 2022 IMPAKTER. All rights reserved.

No Result
View All Result
  • Culture
  • Style
  • Society
  • Impact
  • ECO Products Shop – Try now!
  • INDEX – Sustainability Index
  • UP – Startup Hub
  • About
    • Partners
    • Team
    • Contact
    • Privacy Policy
Impakter.com uses cookies to enhance your experience when visiting the website and to serve you with advertisements that might interest you. By continuing to use this site, you agree to our use of cookies. Visit our Privacy and Cookie Policy.